NCT03302598

Brief Summary

A prospective study of 40 patients admitted with the diagnosis of enterocutaneous fistula and prepared for definite surgical repair in the form of resection anastomosis of ECF. The investigators used preoperative serum C-reactive protein as predicting factor to recurrence and independent variable for timing of surgery.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jan 2015

Typical duration for not_applicable

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 20, 2015

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 20, 2017

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 15, 2017

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

September 24, 2017

Completed
11 days until next milestone

First Posted

Study publicly available on registry

October 5, 2017

Completed
Last Updated

October 6, 2017

Status Verified

October 1, 2017

Enrollment Period

2 years

First QC Date

September 24, 2017

Last Update Submit

October 4, 2017

Conditions

Keywords

enterocutaneous fistula - C-reactive protein- surgical repair

Outcome Measures

Primary Outcomes (1)

  • C-reactive protein can be used as predicting factor for recurrence of ECF after definite surgical treatment as well as helping surgeon to take decision for proper time of operation.

    the investigator will measure the preoperative C-reactive protein in cases of ECF which are scheduled for operative treatment . The level of c-reactive protein will be measured in the postoperative recurrent cases . we aim to find a relation between perioperative level of C-reactive protein and recurrence of ECF so it can help surgeon to choose proper time for surgical treatment to avoid recurrence of ECF

    2 years

Study Arms (1)

patients with enterocutaneous fistula

OTHER
Diagnostic Test: serum C-reactive protein

Interventions

patients with enterocutaneous fistula

Eligibility Criteria

Age56 Years - 77 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • patients with ECF were included in the study

You may not qualify if:

  • Cases submitted for surgical treatment with protecting stoma or terminal were excluded from our study. Other fistulas like perianal, pancreatic, biliary and internal fistulas were not involved due to their different nature, treatment and prognosis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Intestinal Fistula

Condition Hierarchy (Ancestors)

Digestive System FistulaDigestive System DiseasesIntestinal DiseasesGastrointestinal DiseasesFistulaPathological Conditions, AnatomicalPathological Conditions, Signs and Symptoms

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Model Details: A prospective study of 40 patients admitted with the diagnosis of enterocutaneous fistula and prepared for definite surgical repair in the form of resection anastomosis of ECF. the investigators used preoperative serum C-reactive protein as predicting factor to recurrence and independent variable for timing of surgery.
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
assistant professor

Study Record Dates

First Submitted

September 24, 2017

First Posted

October 5, 2017

Study Start

January 20, 2015

Primary Completion

January 20, 2017

Study Completion

April 15, 2017

Last Updated

October 6, 2017

Record last verified: 2017-10